# Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Source: https://onco.cc/trials/nct06821503/  
OnCo record `nct06821503` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Penpulimab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C is a phase 1/2 interventional study registered as NCT06821503 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 72 participants planned, started 2025-04-11 and due to reach its primary completion in 2027-12. Interventions recorded: LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound) and Gemcitabine hydrochloride for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06821503
- Phase: 1/2
- Setting: An Open Label Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab Plus Chemotherapy in Patients With Advanced Solid Tumors - Cohort C
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT06821503: https://clinicaltrials.gov/study/NCT06821503

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Penpulimab](https://onco.cc/drugs/penpulimab/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06821503.json